Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorEuropean Institute of Oncology

About this trial

This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone.

This is a monocentric, prospective observational study.

Eligibility criteria

Qualifiers

Histological diagnosis of castration-resistant prostate cancer,

Single or multiple bone metastases,

Life expectancy of over 6 months,

No current active malignancy other than prostate cancer,

Disqualifiers

Absolute contraindication to WB-MRI, CT or BS,

Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion),

Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.

Trial design

Treatments tested in this trial

  • Imaging evaluation

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators